Table 3.
Diagnoses and procedures in incident GnRH agonist usersa | |||||
SEER groupb | Non-SEER groupc | ||||
n | % | nd | % | p-valuee | |
Procedures related to diagnosis and histologic confirmation of prostate cancera | |||||
Hospitalization | 3691 | 21.2 | 338 | 19.9 | 0.75 |
Transurethral resection of prostate | 1504 | 8.7 | 56 | 3.3 | 0.08 |
Prostate Biopsy | 13728 | 79.0 | 1153 | 67.8 | 0.01 |
Transrectal Ultrasound | 10342 | 59.5 | 868 | 51.1 | 0.11 |
Radical Prostatectomy | 766 | 4.4 | 51 | 3.0 | 0.47 |
Any of the above | 15122 | 87.0 | 1204 | 70.8 | <0.01 |
Other treatment/work-upa | |||||
Radiation Therapy | 3156 | 18.2 | 85 | 5.0 | <0.01 |
CT scan/MRI pelvis | 6421 | 36.9 | 503 | 29.6 | 0.16 |
Bone Scan | 11048 | 63.6 | 910 | 53.5 | 0.06 |
aWithin 3 months before or after diagnosis of prostate cancer (date based on Medicare claims)
bDiagnosis of prostate cancer registered in SEER
cDiagnosis of prostate cancer from Medicare claims, but not in SEER and excluding men who may have had a delay in reporting, moved out of the SEER area at the time of diagnosis or failed the SEER to Medicare linkage
dSample sizes inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
eChi-square test for comparison of proportions between SEER and non-SEER group, based on uninflated sample sizes
GnRH; Gonadotropin-releasing hormone
SEER; Surveillance, Epidemiology and End-Results